Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $204.00 USD
Change Today +1.98 / 0.98%
Volume 1.3M
VRX On Other Exchanges
Symbol
Exchange
Toronto
Mexico
Frankfurt
As of 11:09 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for valeant pharmaceuticals inte (VRX)

Year over year, Valeant Pharmaceuticals International, Inc. has been able to grow their bottom line from a loss of $866.1M USD to a gain of $913.5M USD primarily through revenue growth ($5.6B USD to $8.1B USD). For while the costs associated with cost of goods, SGA and income tax all increased as a percentage of sales, the growth in top line revenues contributed enough to still see net income improve.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Restated
Dec 31
2012
Restated
Dec 31
2013
Restated
Dec 31
2014
4 Year
Trend
Revenues2,427.53,288.65,636.18,097.6
Other Revenues--191.8129.3159.9
TOTAL REVENUES2,427.53,480.45,765.48,257.5
Cost of Goods Sold636.8890.91,528.52,221.3
GROSS PROFIT1,790.62,589.54,236.96,036.2
Selling General & Admin Expenses, Total572.5833.41,305.22,026.3
R&D Expenses65.779.1156.8246.0
Depreciation & Amortization, Total530.1928.91,286.71,463.1
Other Operating Expenses4.122.341.028.4
OTHER OPERATING EXPENSES, TOTAL1,172.31,863.72,789.73,763.8
OPERATING INCOME618.3725.81,447.22,272.4
Interest Expense-334.5-481.6-844.3-971.0
Interest and Investment Income4.16.08.05.0
NET INTEREST EXPENSE-330.4-475.6-836.3-966.0
Currency Exchange Gains (Loss)--19.7-9.4-144.1
Other Non-Operating Income (Expenses)7.5------
EBT, EXCLUDING UNUSUAL ITEMS295.3269.9601.51,162.3
Merger & Restructuring Charges-170.8-424.5-923.6-441.3
Gain (Loss) on Sale of Investments22.82.15.8292.6
Gain (Loss) on Sale of Assets5.3---10.2256.6
Other Unusual Items, Total-170.6-241.7-987.9-177.6
In Process R&D Expenses-----14.4--
Legal Settlements-11.8-56.8-192.550.0
Other Unusual Items-25.9-26.8-35.8-127.5
EBT, INCLUDING UNUSUAL ITEMS-18.0-394.2-1,314.41,092.6
Income Tax Expense-177.6-278.2-450.8180.4
Minority Interest in Earnings-----2.51.3
Earnings from Continuing Operations159.6-116.0-863.6912.2
NET INCOME159.6-116.0-866.1913.5
NET INCOME TO COMMON INCLUDING EXTRA ITEMS159.6-116.0-866.1913.5
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS159.6-116.0-866.1913.5
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $204.02 USD +2.00

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,925 JPY -9.00
Eisai Co Ltd ¥7,907 JPY -335.00
Mylan NV $73.18 USD +1.46
Perrigo Co PLC $188.95 USD +0.67
Sun Pharmaceutical Industries Ltd 924.85 INR -1.55
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 78.6x
Price/Sales 8.5x
Price/Book 13.2x
Price/Cash Flow 30.1x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.